Citi analysts are hopeful that Alvotech will lead the market with its interchangeable high-dose Humira biosimilar, despite the FDA's recent rejection of the AVT04 biosimilar and anticipate a February 2025 launch.
$Alvotech(ALVO.US)$Dont missed out. Medicare will enforced insurance to use biosimolar / generic rather than branded costly meds for auto immune medication as long as its patent is expiring.
Alvotech股票讨论区
In reaction to earnings/guidance:
• $联电(UMC.US)$ +0.8% (August revs)
Other news:
• $ChannelAdvisor(ECOM.US)$ +54.4% (to be acquired for $23.10 per share)
• $IVERIC bio(ISEE.US)$ +42.3% (topline data from Zimura GATHER2 phase 3 clinical trialingeographic atrophy)
• $Monte Rosa Therapeutics(GLUE.US)$ +10% (receives FDA clearance of Investigational New Drug Application for MRT-2359)
• $IDEAYA生物科学(IDYA.US)$ +4.9% (re...
• $Zymergen(ZY.US)$ : JPMorgan Upgrades to Neutral from Underweight
Downgrades
• $Chewy(CHWY.US)$: Wedbush Downgrades to Neutral from Outperform - PT $44 (from $35)
• $派拉蒙环球-B(PARA.US)$: Goldman Sachs Downgrades to Sell from Buy - PT $20 (from $37)
• $Roku Inc(ROKU.US)$: Wolfe Research Downgrades to Underperform from Peerperform - PT $77
• $瑞银(UBS.US)$: BofA Securities Downgrades to Neutral from Buy - P...
暂无评论